ROC analysis was further applied to evaluate the therapeutic efficiencies of TrxR activity as well as existing GC tumor biomarkers CEA, CA72-4, CA19-9 to differentiate between CRP and CUP group (Fig. 4). This evidence concerns the gene CEACAM5 and gastric cancer.